Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Genetic Screening and Functional Characterization of PDGFRB Mutations Associated with Basal Ganglia Calcification of Unknown Etiology
Sánchez-Contreras, Mónica , Finch, NiCole A., Nicholson, Alexandra M., Wojtas, Aleksandra, Ross, Owen A. , Dickson, Dennis W. , Rademakers, Rosa , Baker, Matthew , Wszołek, Zbigniew K. , Dickson, Dennis W , Ross, Owen A , Sanchez-Contreras, Monica

Human Mutation | May 5, 2014 | Volume: 35 | Issue: 8 | Pages: 964-971

10.1002/humu.22582 | PMID 24796542 Get It

AACE Response to Viewpoint of December 9, 2013—Reply
Gionfriddo, Michael R. , McCoy, Rozalina G. , Lipska, Kasia J.

JAMA Internal Medicine | May 5, 2014 | Volume: 174 | Issue: 5 | Pages: 827

10.1001/jamainternmed.2014.166 | PMID 24799017 Get It

Comparative Effectiveness of Cardiac Resynchronization Therapy With an Implantable Cardioverter-Defibrillator Versus Defibrillator Therapy Alone
Masoudi, Frederick A. , Mi, Xiaojuan, Curtis, Lesley H. , Curtis, Jeptha P. , Fonarow, Gregg C. , Hammill, Stephen C., Heidenreich, Paul A. , Piccini, Jonathan P. , Qualls, Laura G., Hernandez, Adrian F. , Peterson, Pamela N. , Al‐Khatib, Sana M. , Qualls, Laura G. , Hernandez, Adrian

Annals of Internal Medicine | May 5, 2014 | Volume: 160 | Issue: 9 | Pages: 603-611

10.7326/m13-1879 | PMID 24798523 Get It

From ‘Solution Shop’ Model To ‘Focused Factory’ In Hospital Surgery: Increasing Care Value And Predictability
Cook, David J. , Thompson, Jeffrey E. , Habermann, Elizabeth B. , Visscher, Sue L. , Roger, Véronique L. , Dearani, Joseph A. , Borah, Bijan J. , Habermann, Elizabeth

Health Affairs | May 5, 2014 | Volume: 33 | Issue: 5 | Pages: 746-755

10.1377/hlthaff.2013.1266 | PMID 24799570 Get It

In vivo dopaminergic and serotonergic dysfunction in DCTN1 gene mutation carriers
Felício, André C. , Dinelle, Katherine, Agarwal, Pankaj , McKenzie, Jessamyn , Heffernan, Nicole, Road, Jeremy , Appel‐Cresswell, Silke , Farrer, Matthew J. , Schulzer, Michael, Stoessl, A. Jon , Wszołek, Zbigniew K. , Sossi, Vesna , Appel-Cresswell, Silke

Movement Disorders | May 5, 2014 | Volume: 29 | Issue: 9 | Pages: 1197-1201

10.1002/mds.25893 | PMID 24797316 Get It

ABSTRACTIntroductionWe used positron emission tomography (PET) to assess dopaminergic and serotonergic terminal density in three subjects carrying a mutation in the DCT1 gene, two clinically affected with Perry syndrome.MethodsAll subjects had brain imaging using 18F‐6‐fluoro‐l‐dopa (FDOPA, dopamine synthesis and storage), (+)‐11C‐dihydrotetrabenazine (DTBZ, vesicular monoamine transporter type 2), and 11C‐raclopride (RAC, dopamine D2/D3 receptors). One subject also underwent PET with 11C‐3‐amino‐4‐(2‐dimethylaminomethyl‐phenylsulfanyl)‐benzonitrile (DASB, serotonin transporter).ResultsFDOPA‐PET and DTBZ‐PET in the affected individuals showed a reduction of striatal tracer uptake. Also, RAC‐PET showed higher uptake in these area. DASB‐PET showed significant uptake changes in left orbitofrontal cortex, bilateral anterior insula, left dorsolateral prefrontal cortex, left orbitofrontal cortex, left posterior cingulate cortex, left caudate, and left ventral striatum.ConclusionsOur data showed evidence of both striatal dopaminergic and widespread cortical/subcortical serotonergic dysfunctions in individuals carrying a mutation in the DCTN1 gene. © 2014 International Parkinson and Movement Disorder Society
Accuracy of Adrenal Imaging and Adrenal Venous Sampling in Predicting Surgical Cure of Primary Aldosteronism
Lim, Vivien , Guo, Qinghua , Grant, Clive S., Thompson, Geoffrey B. , Richards, Melanie L. , Farley, David R. , Young, William F.

The Journal of Clinical Endocrinology & Metabolism | May 5, 2014 | Volume: 99 | Issue: 8 | Pages: 2712-2719

10.1210/jc.2013-4146 | PMID 24796926 Get It

A Case of Blau Syndrome
Chauhan, Krati, Michet, Clement J. , Michet, Clement

Case Reports in Rheumatology | May 4, 2014 | Volume: 2014 | Issue: No issue available | Pages: 1-3

10.1155/2014/216056 | PMID 24876985 Get It

We present a case of systemic granulomatous disorder/Blau syndrome. A patient was seen at our clinic with a diagnosis of Juvenile Idiopathic Arthritis (JIA). He was diagnosed with polyarticular JIA when he was two years old, at that time primary manifestations included inflammation of the hand and wrist joints bilaterally, later he developed ocular symptoms, which were attributed to JIA. He had liver, skin, pulmonary manifestations, and diagnostic workup including biopsy revealed granulomatous inflammation of these sites. During the diagnostic workup, he had worsening of ocular complaints, retinal exam showed panuveitis with multifocal choroiditis. These ocular findings are not seen in JIA, this, along with his other systemic manifestations, led us to revisit the diagnosis. Laboratory testing for genetic mutation for Blau syndrome was done and came back positive. Now all of his systemic findings were placed under one umbrella of systemic granulomatous syndrome/Blau syndrome. Due to worsening of ocular manifestations, he was started on Adalimumab with marked improvement of ocular and systemic manifestations and is followed by team that consists of Rheumatologist, Ophthalmologist, and Gastroenterologist.
Boy With Yellow-Orange, Rough Nodule on Right Thigh
Flores, Sara Elia Hernández, Johnson, Jonathan N. , Young, Phillip M. , Tollefson, Megha M. , Johnson, Jonathan, Young, Phillip, Tollefson, Megha

JAMA Pediatrics | May 3, 2014 | Volume: 168 | Issue: 5 | Pages: 493

10.1001/jamapediatrics.2013.3979 | PMID 24791740 Get It

Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes
Zhang, Xiaodan , Harmsen, William S. , Mettler, Teresa A., Kim, W. Ray , Roberts, Rosebud O., Therneau, Terry M. , Roberts, Lewis R. , Chaiteerakij, Roongruedee , Chaiteerakij, Roongruedee , Roberts, Lewis R

Hepatology | May 3, 2014 | Volume: 60 | Issue: 6 | Pages: 2008-2016

10.1002/hep.27199 | PMID 24798175 Get It

Use of autologous hematopoietic cell transplantation as initial therapy in multiple myeloma and the impact of socio‐geo‐demographic factors in the era of novel agents
Al‐Hamadani, Mohammed , Hashmi, Shahrukh K. , Go, Ronald S. , Go, Ronald S

American Journal of Hematology | May 3, 2014 | Volume: 89 | Issue: 8 | Pages: 825-830

10.1002/ajh.23753 | PMID 24799343 Get It

Very effective combination chemotherapy using novel agents has become available in multiple myeloma (MM). Its impact on the use of high‐dose chemotherapy and autologous hematopoietic stem cell transplantation (AHCT) as part of initial therapy is unknown. Using the National Cancer Data Base, we studied the rate of upfront AHCT use among 137,409 newly diagnosed MM patients from 1998 to 2010 in the United States and determined whether disparity exists among various sociodemographic as well as geographic subgroups. Overall, 12,378 (9.0%) patients received AHCT as part of initial treatment. The use of upfront AHCT increased steadily from 5.2% in 1998 to 12.1% in 2010 (trend test, P < 0.001), with no sign of plateau. This was seen across all socio‐geo‐demographic subgroups except among patients treated in the Northeast where the rate fell from 8.7% in 1998 to 6.6% in 2010. In multivariable analysis, patients with the following characteristics were the least likely to receive AHCT (odds ratio): year of diagnosis from 1998 to 2003 before the era of novel agents (0.67), older age (0.35), Black race (0.58), Hispanic ethnicity (0.78), low level of education or annual household income (0.55), residence in a metro area (0.66), no or unknown medical insurance (0.30), treatment at a community cancer center (0.16), and treatment facility located in the Northeast region (0.54). Even after the introduction of novel agents, the rate of upfront AHCT in MM continues to increase annually. Significant disparities exist dependent on demographic, social, and geographic factors. Am. J. Hematol. 89:825–830, 2014. © 2014 Wiley Periodicals, Inc.